As Covid research heats up, J&J retires a BARDA-funded flu antiviral they worked on for 7 years
The last eight months have seen a resurgence in antivirals as researchers, scrambling for something that might treat Covid-19, repurposed approved HIV drugs and racked …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
